Clene Inc. - Common Stock (CLNN)
Frequently Asked Questions About Clene Inc. - Common Stock (CLNN)
Has Clene Inc. completed any clinical trials?
Yes, Clene Inc. has completed various clinical trials for its lead product candidate CNM-Au8. These trials have assessed the safety, tolerability, and efficacy of the drug in populations with neurodegenerative diseases. The data from these trials is critical in guiding further development and regulatory submissions for these innovative therapies.
How can investors find more information about Clene Inc.?
Investors looking for more information about Clene Inc. can visit the company's official website, where they will find investor resources, financial reports, and updates on clinical programs. Additionally, investors can review filings with the Securities and Exchange Commission (SEC), access transcripts of earnings calls, and follow news releases related to clinical developments and business activities.
How does Clene Inc. approach sustainability?
Clene Inc. is committed to sustainable practices in its operations and product development. The company emphasizes eco-friendly principles in its research processes, including responsible sourcing of materials and utilizing sustainable technology in its operations. This commitment to sustainability aligns with the broader organizational goal of generating positive impact both in healthcare and environmental stewardship.
How does Clene Inc. ensure the safety of its therapies?
Clene Inc. adheres to rigorous clinical trial protocols and regulatory guidelines to ensure the safety of its therapies. The company conducts comprehensive preclinical and clinical studies to assess the safety and tolerability of its product candidates. Continuous monitoring and analysis of data collected during clinical trials contribute to the overall safety profile of the therapies being developed.
Is Clene Inc. publicly traded?
Yes, Clene Inc. is publicly traded on the Nasdaq under the ticker symbol CLNN. The company went public through a reverse merger in 2020, and its shares are available for purchase by retail and institutional investors. Being publicly traded allows Clene to raise capital for its clinical development programs more effectively.
What are the future plans for Clene Inc.?
Clene Inc. plans to continue advancing its clinical pipeline, with a focus on completing clinical trials for CNM-Au8 and exploring additional indications for its product candidates. The company is committed to expanding its research initiatives and forming strategic partnerships to enhance its development capabilities and expedite the delivery of innovative therapies to patients.
What are the key financial aspects of Clene Inc.?
As a publicly traded company, Clene Inc. regularly reports its financial performance, including revenue, expenses, and cash flow. Financial aspects such as research and development spending, general administrative expenses, and funding activities through public markets or partnerships are crucial for understanding the company's operational health and sustainability as it advances its pipeline.
What are the primary goals of Clene Inc.'s clinical studies?
The primary goals of Clene Inc.'s clinical studies are to evaluate the safety and efficacy of their product candidates, understand the pharmacokinetics and pharmacodynamics of their therapies, and gather data to support regulatory submissions. These studies aim to establish whether their treatments can offer meaningful benefits to patients with neurodegenerative diseases, ultimately leading to market approval.
What diseases is Clene Inc. targeting with its therapies?
Clene Inc. primarily targets neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other conditions that impair cognitive and motor functions. The company's innovative approach focuses on developing therapies that can modify disease progression and enhance the quality of life for patients suffering from these debilitating disorders.
What does Clene Inc. do?
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company's primary focus is on harnessing its nanotechnology platform to create a new class of medicines that address severe unmet medical needs. Clene Inc. aims to develop treatments that can improve cognitive and motor functions in diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
What does it mean for Clene Inc. to have Orphan Drug Designation?
Orphan Drug Designation is granted by the FDA to encourage the development of therapies for rare diseases that affect fewer than 200,000 people in the U.S. For Clene Inc., receiving this designation for CNM-Au8 in the treatment of ALS provides several benefits, including tax incentives, exclusivity for a specified period upon approval, and support for clinical development, all aimed at expediting the drug’s development process.
What is Clene Inc.'s lead product candidate?
Clene Inc.'s lead product candidate is CNM-Au8, a gold nanocrystal suspension designed to enhance cellular energy metabolism and provide neuroprotective benefits. This candidate is currently being evaluated in clinical trials for its efficacy in treating ALS and other neurodegenerative diseases. The unique formulation of CNM-Au8 ensures targeted delivery and improved bioavailability in the nervous system.
What is the competitive landscape for Clene Inc.?
Clene Inc. operates in a competitive landscape filled with other biopharmaceutical companies that are also targeting neurodegenerative diseases. Competition includes both established players and emerging biotech firms developing novel therapies. Clene differentiates itself through its unique nanotechnology-based approach, focusing on the mechanistic basis of disease to create innovative solutions that may provide advantages over traditional therapies.
What is the mission of Clene Inc.?
The mission of Clene Inc. is to develop innovative and effective therapies for patients suffering from neurodegenerative diseases. The company is committed to improving the lives of patients by leveraging its cutting-edge nanotechnology platform to create drugs that target the underlying mechanisms of disease, ultimately aiming to enhance neurological functions and quality of life.
What milestones has Clene Inc. achieved recently?
Clene Inc. has achieved several significant milestones, including advancing its lead product candidate, CNM-Au8, through various phases of clinical trials and receiving regulatory designations such as Orphan Drug Status for ALS. Additionally, the company has been successful in securing funding to support its clinical research efforts, allowing it to continue moving forward in its mission.
What technology does Clene Inc. utilize in its product development?
Clene Inc. utilizes a proprietary nanotechnology platform to develop its medicinal products, particularly gold nanocrystals. This technology allows for the formulation of ultra-small particles that can easily penetrate cellular barriers, improve drug delivery systems, and enhance the therapeutic efficacy of their compounds. The nanotechnology approach is central to their development of therapies that aim to improve neurological health.
Where is Clene Inc. headquartered?
Clene Inc. is headquartered in Salt Lake City, Utah. The location provides access to a vibrant life sciences community and enables the company to collaborate with leading researchers and institutions. The headquarters serves as the central hub for Clene's research, development, and administrative activities.
Who are Clene Inc.'s key partners or collaborators?
Clene Inc. collaborates with various research institutions, academic partners, and clinical sites to advance its research and development efforts. These partnerships provide critical expertise, access to clinical trial participants, and facilitate knowledge exchange that supports the company's mission to develop effective therapies for neurodegenerative diseases.
Who is the leadership team at Clene Inc.?
Clene Inc. is led by a team of experienced professionals with a strong background in biopharmaceutical development, clinical research, and business strategy. The leadership team includes experts from various fields who have successfully navigated the complexities of drug development and commercialization, providing strategic direction to the company as it seeks to bring its innovative therapies to market.
What is the current price of Clene Inc. - Common Stock?
The current price of Clene Inc. - Common Stock is 3.000
When was Clene Inc. - Common Stock last traded?
The last trade of Clene Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025